{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T23:09:21Z","timestamp":1778454561615,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":15,"publisher":"Springer US","isbn-type":[{"value":"9781071650363","type":"print"},{"value":"9781071650370","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5037-0_12","type":"book-chapter","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:27:07Z","timestamp":1778452027000},"page":"163-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced Evaluation of T-Cell-Dependent Bispecific Antibodies Using Fluorescence Imaging and In Vivo Models"],"prefix":"10.1007","author":[{"given":"Mikiko","family":"Itsukaichi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yasunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"21","key":"12_CR1","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1038\/s41388-021-01811-8","volume":"40","author":"RS Goydel","year":"2021","unstructured":"Goydel RS, Rader C (2021) Antibody-based cancer therapy. Oncogene 40(21):3655\u20133664","journal-title":"Oncogene"},{"issue":"26","key":"12_CR2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454","journal-title":"N Engl J Med"},{"issue":"8","key":"12_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"27","key":"12_CR4","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","volume":"41","author":"SA Holstein","year":"2023","unstructured":"Holstein SA, Grant SJ, Wildes TM (2023) Chimeric antigen receptor t-cell and bispecific antibody therapy in multiple myeloma: moving into the future. J Clin Oncol: Off J Am Soc Clin Oncol 41(27):4416\u20134429","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"8","key":"12_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","volume":"35","author":"AH Wei","year":"2021","unstructured":"Wei AH, Ribera JM, Larson RA, Ritchie D, Ghobadi A, Chen Y, Anderson A, Dos Santos CE, Franklin J, Kantarjian H (2021) Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia 35(8):2220\u20132231","journal-title":"Leukemia"},{"issue":"18","key":"12_CR6","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, Carlo-Stella C, Offner FC, Sureda A, Salles G, Mart\u00ednez-Lopez J, Crump M, Thomas DN et al (2021) Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol: Off J Am Soc Clin Oncol 39(18):1959\u20131970","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"1","key":"12_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00262-020-02667-9","volume":"70","author":"D Kamakura","year":"2021","unstructured":"Kamakura D, Asano R, Kawai H, Yasunaga M (2021) Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation. Cancer Immunol Immunother 70(1):177\u2013188","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"12_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055\u20131065","journal-title":"Lancet Oncol"},{"issue":"10306","key":"12_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","volume":"398","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Mous R, Clausen MR, Johnson\u00a0P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS et al (2021) Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study. Lancet (London, Engl) 398(10306):1157\u20131169","journal-title":"Lancet (London, Engl)"},{"key":"12_CR10","doi-asserted-by":"crossref","unstructured":"Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T (2021) Overcoming challenges for CD3-bispecific antibody therapy in solid tumors. Cancers 13(2):287","DOI":"10.3390\/cancers13020287"},{"key":"12_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S (2019) Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol 10:168","journal-title":"Front Immunol"},{"issue":"1","key":"12_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 52(1):17\u201335","journal-title":"Immunity"},{"issue":"1","key":"12_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nri3129","volume":"12","author":"G Dranoff","year":"2011","unstructured":"Dranoff G (2011) Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol 12(1):61\u201366","journal-title":"Nat Rev Immunol"},{"key":"12_CR14","first-page":"11","volume":"14","author":"D Kamakura","year":"2021","unstructured":"Kamakura D, Asano R, Yasunaga M (2021) T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity. Pharm (Basel, Switz) 14:11","journal-title":"Pharm (Basel, Switz)"},{"issue":"1","key":"12_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni\u00a0C (2024) Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol 13(1):80","journal-title":"Exp Hematol Oncol"}],"container-title":["Methods in Molecular Biology","Bispecific Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5037-0_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T22:27:08Z","timestamp":1778452028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5037-0_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071650363","9781071650370"],"references-count":15,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5037-0_12","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}